Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to Sell at Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

PYXS has been the topic of several other reports. HC Wainwright boosted their price objective on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday. Zacks Research cut Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Stifel Nicolaus initiated coverage on Pyxis Oncology in a research report on Monday, November 3rd. They set a “buy” rating and a $9.00 target price on the stock. Guggenheim increased their price target on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.28 on Friday. The firm has a market cap of $79.38 million, a price-to-earnings ratio of -0.80 and a beta of 1.37. The firm has a fifty day moving average price of $4.01 and a 200 day moving average price of $2.39. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01. As a group, research analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Large investors have recently bought and sold shares of the business. Bank of America Corp DE grew its position in Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after acquiring an additional 593,853 shares during the last quarter. Longaeva Partners L.P. purchased a new stake in shares of Pyxis Oncology during the third quarter valued at $1,117,000. Citadel Advisors LLC bought a new position in shares of Pyxis Oncology in the third quarter worth about $749,000. Jane Street Group LLC purchased a new position in Pyxis Oncology in the 2nd quarter worth about $370,000. Finally, Schulhoff & Co. Inc. lifted its holdings in Pyxis Oncology by 125.4% during the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.